Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23229296 | 0.87 | — | — | |
| SCHEMBL2376935 | 0.80 | DGAT1 (0.36) | DGAT1NPC1 | |
| SCHEMBL2377597 | 0.79 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL2376267 | 0.78 | NPC1 (0.37) | DGAT1NPC1 | |
| SCHEMBL19203897 | 0.75 | NPC1 (0.34) | DGAT1NPC1 | |
| SCHEMBL23208862 | 0.75 | DGAT1 (0.41) | DGAT1GRIN2B | |
| SCHEMBL23208927 | 0.75 | DGAT1 (0.39) | DGAT1NPC1 | |
| SCHEMBL12791523 | 0.75 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL29734957 | 0.75 | DGAT1 (0.39) | DGAT1NPC1 | |
| SCHEMBL2338793 | 0.75 | DGAT1 (0.35) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | MAPT, CYP3A5, SLC5A1 | DGAT1 4132/4885NPC1 238/4885GRIN2B 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.